Medical claims and current applications of the potent echinocandin antifungals

Recent Patents on Anti-Infective Drug Discovery

Volumn 5, Issue 1, 2010, Pages 58-63

  Smith, Leif ^a   Lu, Shi En ^b  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

Anidulafungin; Caspofungin; Cilofungin; Echinocandins; Micafungin; Pharmacokinetics; Production; Structure

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; CILOFUNGIN; CYCLOPEPTIDE; ECHINOCANDIN; ECHINOCANDIN B; FLUCONAZOLE; FR 901379; MICAFUNGIN; PNEUMOCANDIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BILLING AND CLAIMS; CANDIDIASIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LEUKOPENIA; LIVER FUNCTION TEST; NAUSEA; PATENT; PRIORITY JOURNAL; SIDE EFFECT; STRUCTURE ANALYSIS; VOMITING;

ANIMALS; ANTIFUNGAL AGENTS; DRUG DISCOVERY; ECHINOCANDINS; HUMANS; MOLECULAR STRUCTURE; MYCOSES; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 77953792468     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489110790112563     Document Type: Article

References (70)

1. Epand RM, Vogel HJ. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1999; 1462: 11-28.
2. Eriksson EMY, Jackson DC. Recent advances with TLR2-targeting lipopeptide-based vaccines. Curr Protein Pept Sci 2007; 8: 412-417.
3. Hossain MA, Ghannoum MA. New investigational antifungal agents for treating invasive fungal infections. Expert Opin Invest Drugs 2000; 9: 1797-1813.
4. Shah PM. The need for new therapeutic agents: What is the pipeline? Clin Microbiol Infect 2005; 11: 36-42.
5. Straus SK, Hancock REW. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: Comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta 2006; 1758: 1215-1223.
6. Strieker M, Marahiel MA. The structural diversity of acidic lipopeptide antibiotics. Chembiochem 2009; 10: 607-616.
7. Tossi A. Host Defense peptides: Roles and applications. Curr Protein Pept Sci 2005; 6: 1-3.
8. Zhang LJ, Falla TJ. Host defense peptides for use as potential therapeutics. Curr Opin Invest Drugs 2009; 10: 164-171.
9. Pirri G, Giuliani A, Nicoletto SF, Pizzuto L, Rinaldi AC. Lipopeptides as anti-infectives: A practical perspective. Cent Eur J Biol 2009; 4: 258-273.
10. Japelj B, Zorko M, Majerle A, et al. The acyl group as the central element of the structural organization of antimicrobial lipopeptide. J Am Chem Soc 2007; 129: 1022-1023.
11. Jerala R. Synthetic lipopeptides: A novel class of anti-infectives. Expert Opin Invest Drugs 2007; 16: 1159-1169.
12. Hashimoto S. Micafungin: A sulfated echinocandin. J Antibiot 2009; 62: 27-35.
13. Ikeda F, Tanaka S, Ohki H, et al. Role of micafungin in the antifungal armamentarium. Curr Med Chem 2007; 14: 1263-1275.
14. Falagas ME, Ntziora F, Betsi GI, Samoni G. Caspofungin for the treatment of fungal infections: A systematic review of randomized controlled trials. Int J Antimicro Agent 2007; 29: 136-143.
15. Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006; 106: 466-473.
16. Pfaller MA. Anidulafungin: An echinocandin antifungal. Expert Opin Invest Drugs 2004; 13: 1183-1197.
17. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151.
18. Moore CB, Oakley KL, Denning DW. in vitro Activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect 2001; 7: 11-16.
19. Naeger-Murphy N, Pile JC. Clinical indications for newer antifungal agents. J Hosp Med 2009; 4: 102-111.
20. Pollard DJ, Kirschner TF, Hunt GR, Tong IT, Stieber R, Salmon PM. Scale up of a viscous fungal fermentation: Application of scale-up criteria with regime analysis and operating boundary conditions. Biotechnol Bioeng 2007; 96: 307-317.
21. Osawa AE, Sitrin R, Lee SS. Purification of pneumocandins by preparative silica-gel high-performance liquid chromatography. J Chromatogr 1999; 831: 217-225.
22. Roush DJ, Antia FD, Goklen KE. Preparative high-performance liquid chromatography of echinocandins. J Chromatogr 1998; A827: 373-389.
23. Schwartz RE, Sesin DF, Joshua H, et al. Pneumocandins from Zalerion arboricola. I. Discovery and isolation. J Antibiot 1992; 45: 1853-1866.
24. Connors N, Petersen L, Hughes R, Saini K, Olewinski R, Salmon P. Residual fructose and osmolality affect the levels of pneumocandins B0 and C0 produced by Glarea lozoyensis. Appl Microbiol Biotechnol 2000; 54: 814-818.
25. Petersen LA, Hughes DL, Hughes R, DiMichele L, Salmon P, Connors N. Effects of amino acid and trace element supplementation on pneumocandin production by Glarea lozoyensis: Impact on titer, analogue levels, and the identification of new analogues of pneumocandin B(0). J Ind Microbiol Biotechnol 2001; 26: 216-221.
26. Pollard DJ, Kirschner TF, Hernandez D, Hunt G, Olewinski R, Salmon PM. Pilot-scale process sensitivity studies for the scaleup of a fungal fermentation for the production of pneumocandins. Biotechnol Bioeng 2002; 78: 270-279.
27. Masurekar PS, Fountoulakis JM, Hallada TC, Sosa MS, Kaplan L. Pneumocandins from Zalerion arboricola. II. Modification of product spectrum by mutation and medium manipulation. J Antibiot 1992; 45: 1867-1874.
28. Chandler, M.A., Goklen, K.E., Lee, S.S., Roush, D.J.: US20036610822 (2003).
29. Dobbins, J.R., Kroeff, E.P., Vicenzi, J.T.: US20036506726 (2003).
30. Goklen, K.E., Nti-Gyabaah, J., Antia, F.D., Dahlgren, M.E.: US20077241866 (2007).
31. Hodges RL, Hodges DW, Goggans K, Xuei X, Skatrud P, McGilvray D. Genetic modification of an echinocandin B-producing strain of Aspergillus nidulans to produce mutants blocked in sterigmatocystin biosynthesis. J Ind Microbiol 1994; 13: 372-381.
32. Iwamoto T, Fujie A, Nitta K, Hashimoto S, Okuhara M, Kohsaka M. WF11899A, B and C, novel antifungal lipopeptides. II. Biological properties. J Antibiot 1994; 47: 1092-1097.
33. Kanda M, Tsuboi M, Sakamoto K, Shimizu S, Yamashita M, Honda H. Improvement of FR901379 production by mutant selection and medium optimization. J Biosci Bioeng 2009; 107: 530-534.
34. Yamashita M, Matsuda M, Oohata N, Kanda M, Higaki T. Study of industrial manufacturing methods for Micafungin (FK463). Seibutsu-Kogaku 2005; 83: 123-131.
35. Kanasaki R, Abe F, Kobayashi M, et al. FR220897 and FR220899, novel antifungal lipopeptides from Coleophoma empetri No. 14573. J Antibiot 2006; 59: 149-157.
36. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-d-glucan synthase: Implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 2009; 53: 3690-3699.
37. Ha YS, Covert SF, Momany M. FsFKS1, the 1, 3-beta-glucan synthase from the caspofungin-resistant fungus Fusarium solani. Eukaryotic Cell 2006; 5: 1036-1042.
38. Douglas CM, Foor F, Marrinan JA, et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1, 3-beta-D-glucan synthase. Proc Natl Acad Sci USA 1994; 91: 12907-12911.
39. Radding JA, Heidler SA, Turner W. Photoaffinity analog of the semisynthetic echinocandin LY303366: Identification of echinocandin targets in Candida albicans. Antimicrob Agents Chemother 1998; 42: 1187-1194.
40. Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: Where do we stand after 15 years? J Antimicrob Chemother 2006; 57: 384-410.
41. Nyfeler R, Keller-Schierlein W. Echinocandin B, ein neuartiges polypeptid antibiotikum aus Aspergillus nidulans var echinatus: Isolierung und Bausteine. Helvet Chim Acta 1974; 57: 2459-2477.
42. Keller-Juslen C, Kuhn M, Loosli H-R, Petcher TJ, Weber HP, von Wartburg A. Struktur des cyclopeptid-antibiotikums SL 7810. Tetrahedron Lett 1976; 46: 4147-4150.
43. Koyama G. The crystal and molecular structure of 3-hydroxy-4-methyl-proline. Helv Chim Acta 1974; 57: 2477-2483.
44. Kurokawa N, Ohfune Y. Total synthesis of echinocandins. 2. Total synthesis of echinocandins D via efficient peptide coupling reactions. J Am Chem Soc 1986; 108: 6043-6045.
45. Kurokawa N, Ohfune Y. Total synthesis of echinocandins. 1. Stereocontrolled syntheses of the constituent amino acids. J Am Chem Soc 1986; 108: 6041-6043.
46. Balkovec JM, Black RM, Hammond ML, et al. Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP). J Med Chem 1992; 35: 194-198.
47. Debono M, Turner WW, LaGrandeur L, et al. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): Structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. J Med Chem 1995; 38: 3271-3281.
48. Taft CS, Selitrennikoff CP. Cilofungin inhibition of (1-3)-betaglucan synthase: The lipophilic side chain is essential for inhibition of enzyme activity. J Antibiot 1990; 43: 433-437.
49. Boeck LD, Fukuda DS, Abbott BJ, Debono M. Deacylation of echinocandin B by Actinoplanes utahensis. J Antibiot 1989; 42: 382-388.
50. Debono M, Abbott BJ, Turner JR, et al. Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B. Ann N Y Acad Sci 1988; 544: 152-167.
51. Iwamoto T. Studies on antifungal antibiotics. Ph.D. Thesis University of Tokyo 1996.
52. Hino M, Fujie A, Iwamoto T, et al. Chemical diversity in lipopep tide antifungal antibiotics. J Ind Microbiol Biotechnol 2001; 27: 157-162.
53. Borromeo, P.S., Cohen, J.D., Gregory, G.S., Henle, S.K., Hitchcock, S.A., Jungheim, L.N., Mayhugh, D.R., Shephered, T.A., Turner, W.W.: US20040068094 (2004).
54. Ito, K., Nishihara, Y., Matsurura, M., Kawai, K., Kinoshita, M., Higaki, T., Takase, S., Ohki, H.: US20040082757 (2004).
55. Lal, B., Gund, V.G., Gangopadhyay, A.K.: US20077166572 (2007).
56. Larew, L.A., Milton, N., Sabatowski, J.L., Moder, K.P.: US20060111277 (2006).
57. Ohki, H., Tomishima, M., Yamada, A., Takasugi, H.: US20006107458 (2000).
58. Ohki, H., Tomishima, M., Yamada, A., Takasugi, H.: US20016265536 (2001).
59. Tojo, T., Ohki, H., Shiraishi, N., Matsuya, T., Matsuda, H., Murano, K., Barrett, D., Ogino, T., Matsuda, K., Ichihara, M., Hashimoto, N., Kanda, A., Ohigashi, A.: US20056884868 (2005).
60. Denning DW. Echinocandins: A new class of antifungal. J Antimicrob Chemother 2002; 49: 889-891.
61. Pfaller MA, Boyken L, Hollis RJ, et al. in vitro Susceptibility of invasive isolates of Candida sp. to anidulafungin, caspofungin, and micafungin: Six years of global surveillance. J Clin Microbiol 2008; 46: 150-156.
62. Martã-n Mazuelos E, Rodrã-guez-Tudela JL. in vitro Activity of anidulafungin. Comparison with the activity of other echinocandins. Enferm Infecc Microbiol Clin 2008; 26: 7-13.
63. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofugin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
64. Kuse E-R, Chetchotisakd P, Arns da Cunha C, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomized doubleblind trial. Lancet 2007; 369: 1519-1527.
65. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482.
66. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1392-1402.
67. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
68. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-349.
69. Anidulafungin: ECB, LY 303366, V-echinocandin, VEC, VER 002, VER-02. Drugs RD 2003; 4: 167-173.
70. Bruzzo, G.K., Bartizal, K.F., Flattery-Feighner, A.M.: US2006RE38984 (2006).